Clinical trials: Lower Urinary Tract Symptoms
Overactive Bladder
Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder
The purpose of this study is to evaluate the long-term safety and efficacy of imidafenacin.
- Trial name
- NCT00512785
- Testing
- imidafenacin, KRP-197/ONO-8025
- Where
- 2 sites in Japan
- Volunteers
- 435 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Urinary Incontinence
A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence
The purpose of this study is to is to evaluate the safety and efficacy of OROS® oxybutynin chloride in patients being treated for urge urinary incontinence.
- Trial name
- NCT00269724
- Testing
- OROS® oxybutynin
- Volunteers
- 250 people
- Sponsor
- Alza Corporation, DE, USA
Overactive Bladder
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT01004315
- Testing
- KUC-7483, Tolterodine
- Where
- Japan
- Volunteers
- 750 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Overactive Bladder
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of…
- Trial name
- NCT01729819
- Testing
- Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder
Usability Study of the FemPulse System
The objective of the study is to demonstrate that the FemPulse System can be used as indicated in the Instructions for Use (IFU), as applicable.
- Trial name
- NCT06347380
- Testing
- FemPulse System
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- FemPulse Corporation
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Overactive Bladder
Fesoterodine Flexible Dose Study
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence…
- Trial name
- NCT00536484
- Testing
- Fesoterodine
- Where
- 95 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer
BPH, Lower Urinary Tract Symptoms
Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)
This study will evaluate LycoComfort™ supplementation in alleviating symptoms associated with LUTS, BPH, and general prostate concerns.
- Trial name
- NCT03772808
- Testing
- Lycocomfort
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- LycoRed Ltd.
Benign Prostatic Hyperplasia
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
Investigation of the efficacy and safety of the stable combination of dutasteride and tamsulosin (Dinaplex®) in the Greek population as well as the evaluation of the quality of life of patients with benign prostatic hyperplasia…
- Trial name
- PROSPERITY (NCT04831476)
- Testing
- Patients with Benign Prostate Hyperplasia
- Where
- Greece
- Volunteers
- 1,296 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Overactive Bladder, Urinary Incontinence
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00915525
- Testing
- botulinum toxin Type A
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 829 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Clinical study to examine the efficacy, safety and tolerability of combination therapy of tamsulosin hydrochloride and solifenacin succinate compared to monotherapy of tamsulosin hydrochloride in the treatment of males with LUTS…
- Trial name
- Neptune (NCT01018511)
- Testing
- tamsulosin hydrochloride OCAS 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
- Where
- 118 sites in Austria, Belarus and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Astellas Pharma Europe B.V.
Benign Prostatic Hyperplasia
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device.
- Trial name
- NCT02326454
- Testing
- talaporfin sodium, Saline, Drug Activator 100 J/cm
- Where
- 41 sites in United States
- Volunteers
- 225 people
- Sponsor
- Light Sciences Oncology
Overactive Bladder
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.
- Trial name
- NCT00425100
- Testing
- fesoterodine fumarate
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 516 people
- Sponsor
- Pfizer
Overactive Bladder
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-8025 (KRP-197) in patients with overactive bladder.
- Trial name
- NCT00212706
- Testing
- ONO-8025 (KRP-197)
- Volunteers
- 400 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Overactive Bladder
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis.
- Trial name
- NCT00876447
- Testing
- Botulinum Toxin Type A 300U, Botulinum Toxin Type A 200U
- Where
- 22 sites in United States, Australia and 20 more
- Volunteers
- 397 people
- Sponsor
- Allergan
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.
- Trial name
- NCT00575016
- Testing
- botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U)
- Where
- 6 sites in Egypt, Greece and 4 more
- Volunteers
- 74 people
- Sponsor
- Allergan
Nocturia
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
The purpose of this study was to investigate the long term efficacy and safety of several doses of the Melt formulation of desmopressin in a broad population of adult patients with nocturia.
- Trial name
- NCT00615836
- Testing
- Desmopressin Melt
- Where
- 73 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Ferring Pharmaceuticals
Benign Prostatic Hyperplasia
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
The purpose of this study is to evaluate the safety and efficacy of a single treatment of PRX302 for the treatment of Benign Prostatic Hyperplasia (BPH) as compared to placebo.
- Trial name
- PLUS-1 (NCT01966614)
- Testing
- PRX302
- Where
- 76 sites in United States, Australia and 4 more
- Volunteers
- 479 people
- Sponsor
- Sophiris Bio Corp
Urinary Incontinence
The Effect of the TENA SmartCare Change Indicator on Care Efficiency and Skin Health in Long Term Care Facilities
The purpose of this post market clinical investigation is to demonstrate the performance and safety of the TENA SmartCare Change Indicator when used in a nursing home setting.
- Trial name
- NCT05247047
- Testing
- TENA SmartCare Change Indicator
- Where
- 2 sites in Canada, Germany
- Volunteers
- 108 people
- Sponsor
- Essity Hygiene and Health AB
Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- RELIEF (NCT07640776)
- Testing
- Irreversible Electroporation
- Volunteers
- 40 people
- Sponsor
- Angiodynamics, Inc.